Jacob Johnson
Stock Analyst at Stephens & Co.
(2.85)
# 1,794
Out of 4,967 analysts
75
Total ratings
45.76%
Success rate
8.56%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $245.06 | -2.06% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.25 | -4.00% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $7.61 | -21.16% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $30.54 | +96.46% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $205.82 | +53.05% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $492.72 | +38.01% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $122.32 | +38.98% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $4.32 | +15.74% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $1.39 | +691.37% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $23.01 | +65.15% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $8.86 | +91.87% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.31 | +90.84% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $54.63 | +59.25% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $246.95 | +57.93% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $8.78 | +105.01% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.73 | +119.78% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $25.05 | +15.77% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $163.31 | +130.85% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $245.06
Upside: -2.06%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.25
Upside: -4.00%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $7.61
Upside: -21.16%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $30.54
Upside: +96.46%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $205.82
Upside: +53.05%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $492.72
Upside: +38.01%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $122.32
Upside: +38.98%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $4.32
Upside: +15.74%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.39
Upside: +691.37%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $23.01
Upside: +65.15%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $8.86
Upside: +91.87%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.31
Upside: +90.84%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $54.63
Upside: +59.25%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $246.95
Upside: +57.93%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $8.78
Upside: +105.01%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.73
Upside: +119.78%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $25.05
Upside: +15.77%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $163.31
Upside: +130.85%